Compare Stocks: NXTS, CNSP, TRAW, and ENSC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$5.79 -1.7%	$5.33	$1.90 ▼ $10.59	$8.37M	3.06	8,441 shs	4,814 shs
ENSC Ensysce Biosciences	$0.46 +3.6%	$0.34	$0.23 ▼ $2.75	$8.87M	0.97	3.18 million shs	530,336 shs
NXTS Nexentis Technologies	$1.72 +2.4%	$2.38	$1.43 ▼ $58.75	$2.50M	1.85	30,861 shs	10,117 shs
TRAW Traws Pharma	$0.55 +1.5%	$0.60	$0.43 ▼ $3.27	$8.45M	1.6	86,161 shs	67,291 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	-1.68%	+4.91%	+7.24%	+15.82%	-5.38%
ENSC Ensysce Biosciences	+3.57%	+13.95%	+25.88%	+79.34%	-79.00%
NXTS Nexentis Technologies	+2.38%	-6.52%	-7.03%	-70.34%	-96.75%
TRAW Traws Pharma	+1.49%	-6.75%	-0.69%	-59.85%	-65.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNSP CNS Pharmaceuticals	$5.79 -1.7%	$5.33	$1.90 ▼ $10.59	$8.37M	3.06	8,441 shs	4,814 shs
ENSC Ensysce Biosciences	$0.46 +3.6%	$0.34	$0.23 ▼ $2.75	$8.87M	0.97	3.18 million shs	530,336 shs
NXTS Nexentis Technologies	$1.72 +2.4%	$2.38	$1.43 ▼ $58.75	$2.50M	1.85	30,861 shs	10,117 shs
TRAW Traws Pharma	$0.55 +1.5%	$0.60	$0.43 ▼ $3.27	$8.45M	1.6	86,161 shs	67,291 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNSP CNS Pharmaceuticals	-1.68%	+4.91%	+7.24%	+15.82%	-5.38%
ENSC Ensysce Biosciences	+3.57%	+13.95%	+25.88%	+79.34%	-79.00%
NXTS Nexentis Technologies	+2.38%	-6.52%	-7.03%	-70.34%	-96.75%
TRAW Traws Pharma	+1.49%	-6.75%	-0.69%	-59.85%	-65.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNSP CNS Pharmaceuticals	2.00	Hold	$20.00	245.36% Upside
ENSC Ensysce Biosciences	1.00	Sell	N/A	N/A
NXTS Nexentis Technologies	1.00	Sell	N/A	N/A
TRAW Traws Pharma	1.80	Reduce	$1.00	81.79% Upside

Current Analyst Ratings Breakdown

Latest NXTS, CNSP, TRAW, and ENSC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	TRAW Traws Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$1.00
7/17/2026	CNSP CNS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	ENSC Ensysce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	NXTS Nexentis Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Negative	$1.00
6/18/2026	TRAW Traws Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$1.00
6/15/2026	TRAW Traws Pharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral
6/15/2026	TRAW Traws Pharma	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	$12.45 per share	N/A
ENSC Ensysce Biosciences	$5.07M	1.75	N/A	N/A	($0.06) per share	-7.60
NXTS Nexentis Technologies	$210K	11.88	N/A	N/A	$1.23 per share	1.40
TRAW Traws Pharma	$2.79M	3.03	$0.76 per share	0.72	$0.11 per share	5.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNSP CNS Pharmaceuticals	-$15.85M	-$23.59	N/A	N/A	N/A	N/A	-204.25%	-141.87%	11/18/2026 (Estimated)
ENSC Ensysce Biosciences	-$10.18M	-$2.76	N/A	N/A	N/A	-280.53%	-2,550.30%	-320.49%	11/13/2026 (Estimated)
NXTS Nexentis Technologies	-$4M	-$96.07	N/A	N/A	N/A	N/A	-304.79%	-178.91%	N/A
TRAW Traws Pharma	$9.17M	-$1.74	N/A	N/A	N/A	N/A	-23,868.92%	-165.52%	11/12/2026 (Estimated)

Latest NXTS, CNSP, TRAW, and ENSC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TRAW Traws Pharma	-$0.3350	-$0.16	+$0.1750	-$0.16	N/A	N/A
8/13/2026	Q2 2026	ENSC Ensysce Biosciences	-$0.20	-$0.20	N/A	-$0.20	$1.20 million	$1.16 million
8/12/2026	Q2 2026	CNSP CNS Pharmaceuticals	-$0.24	-$0.38	-$0.14	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENSC Ensysce Biosciences	N/A	N/A	N/A	N/A	N/A
NXTS Nexentis Technologies	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNSP CNS Pharmaceuticals	N/A	5.86	5.86
ENSC Ensysce Biosciences	N/A	0.70	0.70
NXTS Nexentis Technologies	0.12	3.72	3.72
TRAW Traws Pharma	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNSP CNS Pharmaceuticals	14.02%
ENSC Ensysce Biosciences	5.63%
NXTS Nexentis Technologies	61.24%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
CNSP CNS Pharmaceuticals	1.82%
ENSC Ensysce Biosciences	2.80%
NXTS Nexentis Technologies	6.52%
TRAW Traws Pharma	7.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNSP CNS Pharmaceuticals	5	1.46 million	1.43 million	Not Optionable
ENSC Ensysce Biosciences	10	19.46 million	18.91 million	Not Optionable
NXTS Nexentis Technologies	2	1.45 million	1.36 million	N/A
TRAW Traws Pharma	17	15.37 million	14.21 million	No Data

NXTS, CNSP, TRAW, and ENSC Headlines

Recent News About These Companies

Traws Pharma shares rise after Q2 loss comes in better than expected

August 17, 2026 | finance.yahoo.com

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

August 14, 2026 | globenewswire.com

Traws Pharma Announces New At-The-Market Offering Program

July 10, 2026 | tipranks.com

Traws Pharma Stock Dividends | NASDAQ:TRAW | Benzinga

July 8, 2026 | benzinga.com

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

June 22, 2026 | globenewswire.com

Outlook for Bucks County biotech take another hit with second setback for flu drug

June 15, 2026 | bizjournals.com

Traws defers midphase flu study after negative regulatory review

June 15, 2026 | fiercebiotech.comF

Micron, Nebius surge premarket; Traws Pharma tumbles

June 15, 2026 | finance.yahoo.com

Traws Pharma shares slide after UK regulator postpones influenza study

June 15, 2026 | msn.com

Why did TRAW stock slump 28% after hours?

June 13, 2026 | msn.com

Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review

June 12, 2026 | quiverquant.comQ

Traws Pharma Provides Regulatory Update on Influenza Program

June 12, 2026 | globenewswire.com

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

May 27, 2026 | globenewswire.com

Traws Pharma Updates ATM Equity Offering Prospectus Supplements

May 26, 2026 | tipranks.com

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026 | globenewswire.com

Traws Pops on Hantavirus Research

May 9, 2026 | baystreet.ca

A hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gains

May 9, 2026 | msn.com

Traws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship Outbreak

May 8, 2026 | benzinga.com

Traws Pharma Advances Development of Clinical Candidates for Hantavirus Treatment

May 8, 2026 | quiverquant.comQ

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

May 8, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTS, CNSP, TRAW, and ENSC Company Descriptions

CNS Pharmaceuticals NASDAQ:CNSP

$5.79 -0.10 (-1.68%)

As of 09/4/2026 03:53 PM Eastern

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Ensysce Biosciences NASDAQ:ENSC

$0.46 +0.02 (+3.57%)

As of 09/4/2026 04:00 PM Eastern

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Nexentis Technologies NASDAQ:NXTS

$1.72 +0.04 (+2.38%)

As of 09/4/2026 04:00 PM Eastern

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

Traws Pharma NASDAQ:TRAW

$0.55 +0.01 (+1.49%)

As of 09/4/2026 04:00 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NXTS, CNSP, TRAW, and ENSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NXTS, CNSP, TRAW, and ENSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NXTS, CNSP, TRAW, and ENSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTS, CNSP, TRAW, and ENSC Company Descriptions

CNS Pharmaceuticals NASDAQ:CNSP

Ensysce Biosciences NASDAQ:ENSC

Nexentis Technologies NASDAQ:NXTS

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NXTS, CNSP, TRAW, and ENSC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NXTS, CNSP, TRAW, and ENSC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NXTS, CNSP, TRAW, and ENSC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTS, CNSP, TRAW, and ENSC Company Descriptions

CNS Pharmaceuticals NASDAQ:CNSP

Ensysce Biosciences NASDAQ:ENSC

Nexentis Technologies NASDAQ:NXTS

Traws Pharma NASDAQ:TRAW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools